Tysabri and PML: What Georgia Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri (natalizumab) for multiple sclerosis or Crohn's disease, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection requires prompt recognition and management. The medical community has long studied the balance between Tysabri's benefits and its risks, and this page provides a clear overview of PML symptoms, risk factors, and monitoring strategies for Georgia patients.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic medication approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its prescribing information carries a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI and detection of JCV DNA in cerebrospinal fluid. Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow reactivation of latent JCV, leading to PML.

Georgia Statute of Limitations for Tysabri-Related PML Claims

For patients in Georgia who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a claim. In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML can have a variable onset, with symptoms appearing months to years after starting Tysabri. The duration of treatment prior to PML onset can range from a few months to several years, as noted in postmarketing reports of herpes infections in Tysabri-treated patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For PML specifically, the risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adequacy of warnings is a key issue in potential legal claims. The boxed warning clearly states that Tysabri increases the risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude of risk, the need for regular monitoring, and the importance of early detection. The TOUCH program is designed to ensure that patients are educated about risks, but compliance and effectiveness can vary.

Legal Considerations for Affected Patients

Attorney-related considerations for affected patients include the need to document the timeline of Tysabri exposure, onset of PML symptoms, and diagnosis. Medical records, including MRI reports, CSF analysis results, and documentation of anti-JCV antibody status, are essential. Patients should also preserve records of all communications with healthcare providers about Tysabri risks, including any discussions about the TOUCH program. The statute of limitations in Georgia requires prompt action after discovery of the injury, so consulting with an attorney experienced in pharmaceutical litigation is advisable. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors identified in its prescribing information. For patients in Georgia who have developed PML, legal claims must be filed within the state's statute of limitations, typically two years from discovery of the injury. Adequacy of warnings and the timeline between exposure and harm are central to such claims. Affected individuals should seek legal counsel to evaluate their specific circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Georgia?

In Georgia, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Tysabri, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML can have a variable onset, and delays in diagnosis may affect the filing deadline.

What are the risk factors for developing PML while on Tysabri?

Three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

How is PML diagnosed in Tysabri-treated patients?

Diagnosis typically involves brain MRI and detection of JCV DNA in cerebrospinal fluid. Healthcare professionals are instructed to monitor for any new signs or symptoms suggestive of PML and to withhold dosing immediately if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.